DEJ

CtrlStack Launches with $5.2 Million Seed Funding Led by Sequoia Capital to Deliver Real-Time Troubleshooting

Retrieved on: 
Thursday, December 15, 2022
Knowledge, RCA, Root cause analysis, Environment, DEJ, Life, Speed of light, Intelligence, VMware, Multimedia, Sequoia Capital, Organization, MTTR, SAN, Machine learning, Anxiety, Engineering, Pressure, Risk management, Online shopping, Wavefront, DevOps

Now, Dev and the team at CtrlStack are creating a unified experience for handling the challenges of troubleshooting complex, distributed systems.

Key Points: 
  • Now, Dev and the team at CtrlStack are creating a unified experience for handling the challenges of troubleshooting complex, distributed systems.
  • Businesses are under unprecedented pressure to deliver digital services and applications faster than ever before.
  • Bill Coughran, Partner at Sequoia Capital, said: "A flawless digital experience is now the baseline for every business in order to stay competitive.
  • Harnessing the power of those connections, CtrlStack enables automated troubleshooting and serves as the system of record for change management.

Revision Skincare® Launches D-E-J Daily Boosting Serum™

Retrieved on: 
Tuesday, November 1, 2022
Cream, Research and development, CEO, Health, Neuroscience, Human, Brain, Time, Technology, Industry, DEJ, Skin care, Skin, Elasticity, Serum, Multimedia, Elastin, Gene, Cosmetics

DALLAS, Nov. 1, 2022 /PRNewswire/ -- Revision Skincare®, a leading medical-grade professional skincare brand, today announces the launch of its newest innovation in their D-E-J® Age-Defying Power Regimen: D-E-J Daily Boosting Serum™. Designed to improve the healthy function of the skin's Dermal-Epidermal Junction (DEJ), a critical factor in skin aging, this energizing serum visibly improves radiance and skin firmness while reducing the appearance of fine lines and overall photodamage.

Key Points: 
  • DALLAS, Nov. 1, 2022 /PRNewswire/ --Revision Skincare, a leading medical-grade professional skincare brand, today announces the launch of its newest innovation in their D-E-J Age-Defying Power Regimen: D-E-J Daily Boosting Serum.
  • D-E-J Daily Boosting Serum works quickly to deliver visible results, with significant improvements in skin appearance over time, according to clinical studies that show:
    After just 7 days* D-E-J Daily Boosting Serum is clinically proven to increase skin radiance, smooth skin texture, and reduce the appearance of fine lines.
  • Additionally:
    100% of study participants agreed that their overall skin appearance was improved, and their skin's youthful vitality was boosted
    After 12 weeks*, the following average improvements from baseline were seen:
    "From our inception, Revision Skincare has been focused on launching industry-first technologies generating clinically-validated results, and D-E-J Daily Boosting Serum is no different," adds Maria Carell, CEO and President, Revision Skincare.
  • D-E-J Daily Boosting Serum joins Revision Skincare's powerhouse D-E-J Age-Defying Power Regimen consisting of D-E-J Eye Cream , D-E-J Face Cream , and D-E-J Night Face Cream .

Login VSI Named as Top 20 Emerging Vendor by DEJ

Retrieved on: 
Wednesday, October 12, 2022
Apps, Applications, Technology, Mobile, Wireless, Security, Telecommunications, Software, Networks, Data Management, Artificial Intelligence, Organization, Login VSI, Industry, Risk, Research, IT, CEO, Investment, Solution, DEJ, VDI, Online shopping, Public relations

Login VSI, the company that provides the industry's first digital workspace reliability platform, announced today that Digital Enterprise Journal (DEJ), a business technology research firm, has named Login VSI to its 2022 Emerging Vendors list in managing IT performance in a recent report.

Key Points: 
  • Login VSI, the company that provides the industry's first digital workspace reliability platform, announced today that Digital Enterprise Journal (DEJ), a business technology research firm, has named Login VSI to its 2022 Emerging Vendors list in managing IT performance in a recent report.
  • "Login VSI's insights into the VDI chain of service drive better employee experiences.
  • Simic also noted that Login VSI is well aligned "with user requirements in categories such as optimization and visibility into inefficiencies."
  • "We are honored to be recognized by DEJ as one of its top 20 emerging vendors for managing IT performance," said Eric Jan van Leeuwen, CEO of Login VSI.

Pliant Named as Top 20 Vendor

Retrieved on: 
Thursday, September 29, 2022
Data Management, Technology, Other Technology, Telecommunications, Software, Networks, Internet, API, DEJ, TOPS-20, Automation, Organization, Technology, Classification, Solution, Efficiency, Communication, ML, Online shopping, Sales

Pliant, a leading provider of API-driven orchestration and automation solutions today announced that it has been named a Top 20 Emerging Vendor for Managing IT Performance in 2022 by technology research firm Digital Enterprise Journal (DEJ).

Key Points: 
  • Pliant, a leading provider of API-driven orchestration and automation solutions today announced that it has been named a Top 20 Emerging Vendor for Managing IT Performance in 2022 by technology research firm Digital Enterprise Journal (DEJ).
  • Pliant provides businesses with an orchestration platform that automates, integrates, and connects the digital enterprise.
  • It earned its Top 20 spot through its strong showing in eight key areas examined in the report.
  • Pliant is honored by the recognition from DEJ in this thorough and well-researched study, said Vess Bakalov, Pliant Founder and Chief Executive Officer.

OpsRamp Named to DEJ’s List of Top 20 Vendors for Managing IT Performance in 2022

Retrieved on: 
Thursday, July 21, 2022
GLOBE, SAN, Research, Glass, Artificial intelligence, DEJ, Organization, Leadership, Machine learning, PTP, Pain, Software as a service, MSP, TOPS-20, Member of the Scottish Parliament, Automation, Risk management

SAN JOSE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- OpsRamp, the digital operations management company, has been named a Top 20 Vendor for Managing IT Performance in 2022 by technology industry research firm Digital Enterprise Journal (DEJ).

Key Points: 
  • SAN JOSE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- OpsRamp, the digital operations management company, has been named a Top 20 Vendor for Managing IT Performance in 2022 by technology industry research firm Digital Enterprise Journal (DEJ).
  • The designation is a follow-up to DEJs market study titled 24 Key Areas Shaping IT Performance Markets in 2022 .
  • Download DEJs full report, 24 Key Areas Shaping IT Performance Markets in 2022 here .
  • After you download this report, we will email you a copy of OpsRamps listing in DEJs Top 20 Vendors for Managing IT Performance in 2022 report.

BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Retrieved on: 
Friday, May 20, 2022
Disease, Research, Food, Pain management, Trauma, SID, Lists of diseases, Drug Quality and Security Act, Twitter, SEC, PHASE 2, Mouth, Annual report, Epidermis, Pain, VII, Bart syndrome, Clinical trial, Securities Act of 1933, Intention, Securities Exchange Act of 1934, Genetic disorder, Acid erosion, GLOBE, Concha bullosa, Epidermolysis bullosa, Survival, Tongue, DEB, Science, Patient, RDEB, Lewis Milestone, DEJ, Eye, C7, FDA, European Medicines Agency, PALO, Skin, Society, LinkedIn, Squamous cell carcinoma, Genetic distance, Radioactive decay, Cancer, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Environment, Poster, Esophagus, Tearing, Safety, Wound healing, Malnutrition, Instrument, Scar, Pharmaceutical industry, Dentistry, Medical imaging

PALO ALTO, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022 between May 18 – 21, 2022 in Portland, Oregon.

Key Points: 
  • Our data shows that treatment with PTR-01 led to rapid, consistent, and durable wound healing, said Sanuj K. Ravindran, M.D., executive chairman of Phoenix Tissue Repair.
  • Phoenix Tissue Repair is an affiliate company of BridgeBio and focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB).
  • PTR-01 is an investigational protein replacement therapy which uses a recombinant collagen type VII (rC7) for the treatment of RDEB.
  • Moreover, BridgeBio and Phoenix Tissue Repair operate in very competitive and rapidly changing environments in which new risks emerge from time to time.